Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women

Diabetes Care

Volumn 20, Issue 11, 1997, Pages 1697-1701

  Kamath, Vinaya ^a   Jones, Claire N ^a   Yip, Jeannie C ^a   Varasteh, Ben B ^a   Cincotta, Anthony H ^b   Reaven, Gerald M ^b   Chen, Yii Der I ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CHOLESTEROL; FATTY ACID; GLUCOSE; INSULIN; LIPID; LIPOPROTEIN; PROLACTIN; SOMATOSTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; CARBOHYDRATE METABOLISM; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; DRUG DELIVERY SYSTEM; DRUG RELEASE; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; OBESITY; PROLACTIN BLOOD LEVEL;

EID: 0030829193     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.20.11.1697     Document Type: Article

References (24)

1. Pond CM: Morphological aspects and the ecological and mechanical consequences of fat deposition in wild vertebrates. Annu Rec Ecol Syst 9:519-570, 1978
2. Young RA: Fat, energy and mammalian sur-vival. Am Zoo! 16:699-710,1976
3. Ferrannini E, Barren EJ, Bevilacqua S, DeFronzo R: Effect of fatty acids on glucose production and utilization in man. J Gin Invest 72:1737-1747,1983
4. Miller LJ, Meicr AH: Temporal synergism of neurotransmitter-affecting drugs influences seasonal conditions in sparrows. J Interdiscipl Cycle Res 14:75-84,1982
5. Emata AC, Meicr AH, Spicler RE: Temporal variations in gondola and body fat responses to daily injections of 5-hydroxytryptophan (5-HTP) and dihydroxyphenylalanine (DOPA) in the Gulf Killifish, Fundulus grandis. J Exp Zoo! 233:29-34,1985
6. Wilson JM, Meicr AH: Resetting the annual cycle with timed daily injections of 5hydroxytryptophan and 1-dihydroxyphenylalanine in Syrian hamsters. Chronobio! Int 6:113-121,1989
7. Cincotta AH, MacEachem TA, Meicr AH: Bromocriptine redirects metabolism and prevents seasonal onset of obese hyperinsulinemic state in Syrian hamsters. Am J Physio! 264:E285-E293,1993
8. Cincotta AH, Meicr AH: Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters (Mesocricetus auratus). Metabolism 44:1349-1355,1995
9. Cincotta AH, Meicr AH: Bromocriptine (Ergoset) reduces body weight and improves glucose intolerance in obese subjects. Diabetes Care 19:667-670, 1996
10. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categorics of glucose intolerance. Diabetes 28:1039-1057,1979
11. Kadish AH, Litle RL, Stemberg JC: A new and rapid method for determination of glucose by measurement of rate of oxygen consumption. Clin Chem 14:116-131,1968
12. Hales CN, Randle PJ: Immunoassay of insulin with insulin-antibody precipitate. BiochemJ 88:137-146,1963
13. Wahlefeld AW: Triglycerides: determination after enzymatic hydrolysis. In Method's oj Enzymatic Analysis. Vol. 11. Bergmeyer HU, Ed. New York, Academic, 1974, p. 1831-1835
14. Noma A, Okabe H, Kita M: A new calorimetric micro-determination of free fatty acids in serum. Clin ChimActa 43:317-320,1973
15. Paris N, Roben R, Mercicr I: Monoclonal antibodics against methionyl recombinant human prolactin. Hybridbma 12:107-113, 1993
16. Chen Y-DI, Swami S, Skoeronski R, Coulston A, Reaven GM: Differences in postprandial lipemia between paticnts with normal glucose tolerance and non-insulindependent diabetes mellitus. J Endocrine! Metab 76:172-177,1993
17. Shen D-C, Shich S-M, Fuh M-T, Wu D-A, Chen Y-DI, Reaven GM: Resistance to insulin-mediated glucose uptake in paticnts with hypertension. J Gin Endocrine! Metab 66:580-583,1988
18. Shen S-W, Reaven GM, FarquharJ: Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes. J Clin Invest 49:2151-2160,1970
19. Cronin MJ, Evans WS, Thorner MO: One minute of bromocriptine irreversibly inhibits prolactin release for hours. Eur J Pharm 99:85-90, 1984
20. Jeng C-Y, Fuh MM-T, Sheu WH-H, Chen YDl, Reaven GM: Hormone and substrate modulation of plasma triglycéride concentration in primary hypertriglyceridaemia. EndocrinolMetab 1:15-21, 1994
21. PullingerCR,NorthJD.TengBB, RificiVA, Ronhild de Brito AE, Scott J: The apolipoprotein B gene is constitutively expressed in HepG2 cells: regulation of secretion by oleic acid, albumin, and insulin, and measurement of mRNA halflife. ] Lipid Res 30:1065-1077,1989
22. Dixon JL, Furukawa S, Ginsberg HN: Oleate stimulates secretion of apolipoprotein B-containing lipoproteins from Hep G2 cells by inhibiting early intracellular degradation of apolipoprotein B. J Bio! Chem 266:5080-5086, 1991
23. Cincotta AH, Schiller BC, Meicr AH: Bromocriptine inhibits the seasonally occurring obesity, hyperinsulinemia, insulin resistance, and impaired glucose tolerance in the Syrian hamster, Mesocricetus auratus. Metabolism 40:639-644,1991
24. Cincotta AH, Meicr AH, Haag B, Raskin P: Bromocriptine (Ergoset™ improves glycemic control in obese-NlDDM subjects (Abstract). Diabetes 44 (Suppl 1):69A, 1995